Table_1_Global burden of lower respiratory infections during the last three decades.DOCX by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Image_15_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Image_3_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Presentation_1_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Image_12_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Image_10_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Presentation_3_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Table_4_Global burden of lower respiratory infections during the last three decades.DOC by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Image_2_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Image_4_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Image_6_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Image_7_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Image_13_Global burden of lower respiratory infections during the last three decades.PDF by Saeid Safiri (3713035)

“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”

Table_2_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.xlsx by Tianmeng Yan (16682754)

“…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”

NTS_QECH by Catherine Wilson (8586315)

“…Estimated minimum incidence of iNTS disease decreased from 21/100,000 per year in 2011 to 7/100,000 per year in 2019. …”

Table_1_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.docx by Tianmeng Yan (16682754)

“…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”

Table_3_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.xlsx by Tianmeng Yan (16682754)

“…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”

Table_1_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.docx by Tianmeng Yan (16682754)

“…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”

Increased CN inhibition leads to reduced STO frequency and to more CSpk frequency. by Elías M. Fernández Santoro (22470299)

“…<p>(A) After Plasticity difference for SSpks is significant across coupled cases for the Upbound zone (t = 4.51, p < 0.001; two-sample Student’s t-test; n = 100) and for coupled case across zones (t = -5.36, p < 0.001; two-sample Student’s t-test; n = 100). …”

DataSheet_1_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.docx by Tianmeng Yan (16682754)

“…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”